niraparib

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

niraparib

Trade Name(s):

Zejula

NCI Definition [1]:

An orally bioavailable inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.

Biomarker-Directed Therapies

Niraparib can be used in the treatment of fallopian tube carcinoma, malignant ovarian neoplasm, and primary peritoneal carcinoma. BRCA1, BRCA1 Mutation, and BRCA2 are the most frequent biomarker inclusion criteria for use of niraparib [2].

Fallopian Tube Carcinoma +

Disease is predicted to be sensitive to niraparib: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive

Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)

Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive	Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)
	Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Malignant Ovarian Neoplasm +

Disease is predicted to be sensitive to niraparib: -

Biomarker Criteria:

Sample must match one or more of the following:

BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive

Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)

Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Biomarker Criteria: Sample must match one or more of the following: BRCA1 Mutation, BRCA2 Mutation, Myriad myChoice HRD Positive	Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN)
	Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens.

Primary Peritoneal Carcinoma +

Clinical Trials

View Clinical Trials for niraparib

Niraparib has been investigated in 72 clinical trials, of which 66 are open and 6 are closed. Of the trials investigating niraparib, 23 are phase 1 (19 open), 11 are phase 1/phase 2 (10 open), 31 are phase 2 (30 open), and 7 are phase 3 (7 open).

BRCA1 Loss, BRCA1 Mutation, and BRCA2 Loss are the most frequent biomarker inclusion criteria for niraparib clinical trials.

Breast carcinoma, malignant solid tumor, and fallopian tube carcinoma are the most common diseases being investigated in niraparib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Niraparib

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Niraparib

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating niraparib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

mk4827, niraparib, parp inhibitor mk4827, mk 4827, 2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide, mk-4827, Zejula

Drug Categories [2]:

PARP inhibitors

Drug Target(s) [2]:

PARP1, PARP2

NCIT ID [1]:

C80059

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /